[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"haemophilia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:haemophilia":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100578336","synovial-proliferation-on-routine-ultrasound-active-or-inactive-100578336",false,"NCT06809972","Synovial Proliferation on Routine Ultrasound: Active or Inactive?","Synovial Proliferation on Routine Ultrasound: Active or Inactive? A Prospective Study","2BEGIN","Inclusion Criteria:\n\n* Gender: male\n* Patients with severe haemophilia A or B\n* Treated with registered prophylaxis medication including coagulation factors and by- passing agents.\n* Age ≥ 12 years\n* Subclinical synovial proliferation in ≥1 joint (ankle, knee and\u002For elbow), defined as the presence of hypertrophic synovium, score \\>0 according to the HEAD-US protocol, as confirmed during routine ultrasound screening.\n* Able to give written informed consent.\n\nExclusion Criteria:\n\n* A major bleed ≤ 3 months or a minor bleed ≤ 1 month prior to inclusion in the joint of interest.\n* On demand therapy.\n* Currently treated with any type of haemophilia prophylaxis medication.\n* Joints with prosthesis or treated with arthrodesis will not be included for physical examination and ultrasound analysis. However, participants may still be included in the study with their other joints.\n* Confirmed inflammatory joint diseases such as rheumatoid arthritis or psoriatic arthritis.\n* History of inhibitor development (≥ 5 Bethesda Units\\* (BU) at any time or 1-5 BU for\n\n  * 1 year prior to inclusion.\n* Contra-indication for treatment with NSAIDs, (allergy, severe liver failure, renal failure (GFR \\\u003C30ml\u002Fmin), congestive heart failure (NYHA II-IV), peripheral arterial disease and\u002For cerebrovascular disease.","MALE","12 Years",{"count":20,"type":21},46,"ESTIMATED","OBSERVATIONAL","There is cumulating evidence for the presence of non-observed or subclinical joint bleeding in patients with haemophilia. Early detection of active subclinical synovial proliferation would allow early intervention in order to prevent deterioration of joint health. Patients with subclinical (=non-observed) signs of synovial proliferation in knee(s), ankle(s) and\u002For elbow(s) will be invited to participate in this study to further characterize the synovial proliferation status (active or inactive) by means of physical examination, MRI, ultrasound and elastography. Synovial proliferation status will be monitored for a maximum period of 12 weeks, during which participants will also receive standard-of-care treatment, i.e. administration of optimized coagulation factor replacement therapy and prescription of the NSAID celecoxib (optional).",[25,26,27],"Haemophilia","Hemophilia A","Hemophilia B",[29,30,31,32],"Subclinical synovial proliferation","Ultrasound","MRI","Elastography","RECRUITING","2026-04-28",{"date":36,"type":37},"2026-05-05","ACTUAL",{"date":39,"type":37},"2025-06-01",{"date":41,"type":21},"2028-04-01",{"name":43,"class":44},"Van Creveldkliniek","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":45},"100570358","the-cache-study-coronary-artery-care-in-haemophilia-100570358","NCT06706206","The CACHE Study: Coronary Artery Care in HaEmophilia","CACHE","Inclusion Criteria:\n\n* Be willing and able to give informed consent for participation in the study.\n* Male, aged 45 years or above (no upper age limit).\n* Haemophilia A or B with Factor VIII\u002FIX less than 40% (0.40 IU\u002Fml).\n\nExclusion Criteria:\n\n* Participants unable or unwilling to give informed consent.\n* Participants unable to understand the English language.\n* Participants unable or unwilling to attend for the necessary scans and investigations.\n* Patients with absolute contra-indications to CT imaging will be excluded from the study. This includes:\n\n  * Any known contraindications to CT iodinated Contrast.\n  * Significant renal impairment (eGFR \\\u003C30 ml\u002Fmin).\n* Any other medical conditions which would influence the reliability of the study results determined by the investigators.","45 Years","120 Years",{"count":56,"type":21},80,"The investigators will use state-of-the-art imaging to look at heart disease in people with haemophilia. Haemophilia is an inherited disorder in which blood does not clot properly because of lack of a key 'glue' blood component (chemicals known as factor VIII or IX). People with haemophilia are 40% less likely to die of heart disease, but it is not known exactly why this is. Understanding heart disease in people with haemophilia is important because better treatments for haemophilia mean that these patients are now living longer, but doctors still don't know if the risk for heart disease in these patients as they age is the same as that for the general population. If these processes are better understand (perhaps less blood clotting is actually protecting the heart from blockage-causing clots), scientists might be able to reduce the risk of heart attacks for everybody.\n\nThe UK's first photon-counting detector cardiac CT scanner generates detailed images of the heart and its blood vessels by counting individual X-ray photons. Together with artificial intelligence tools, it is possible to extract a lot of information from these images. As people age, fat is deposited in the vessels which supply blood to the heart which forms plaques. Plaques cause narrowing of the vessels, reducing blood flow to the heart, and can also burst (rupture), leading to a blood clot and heart attack. The new CT scan will show the type and amount of plaques, and quantify the risk of plaque rupture, in people with haemophilia; and the investigators will compare this to people without haemophilia.\n\nUnderstanding the role of factor VIII\u002FIX in heart attacks will improve management of heart disease in people with haemophilia, and may also lead to new prevention and treatment strategies that benefit heart health for everyone.",[25,59],"Cardiovascular Diseases","2026-03-09",{"date":62,"type":37},"2026-03-11",{"date":64,"type":37},"2025-02-25",{"date":66,"type":21},"2032-01",{"name":68,"class":44},"Oxford University Hospitals NHS Trust",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":81,"conditions":82,"keywords":83,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":99},"100625145","determinants-and-consequences-of-the-transition-to-adulthood-for-adolescents-with-severe-haemophilia-transhemo-2-an-ancillary-study-to-the-transhemo-project-100625145","NCT07418827","Determinants and Consequences of the Transition to Adulthood for Adolescents With Severe Haemophilia: TRANSHEMO 2, an Ancillary Study to the TRANSHEMO Project","TRANSHEMO2","Inclusion Criteria:\n\n* Young adults who participated in the TRANSHEMO project during adolescence and who are currently aged 20-29 years;\n* Young adults with severe haemophilia (haemophilia A or B);\n* Young adults registered in the FranceCoag registry;\n* Young adults who have received the participant information sheet for the TRANSHEMO 2 project;\n* Young adults who did not object to participation in the present study.\n\nExclusion Criteria:\n\n* patients with comprehension difficulties;\n* patients who are unable to read and\u002For write;\n* patients who express opposition to participation in this study.","ALL","20 Years","29 Years",{"count":80,"type":21},75,"Haemophilia is a rare genetic disorder which, in its severe form and in the absence of treatment, can be life-threatening. Since the 1960s and the introduction of coagulation factor concentrates, the life expectancy of people with haemophilia has increased rapidly. Today, for most affected individuals, the disease is experienced as a chronic condition.\n\nThe transition process enabling adolescents and young adults (AYA) with a chronic disease to move into adult life can be complex, as they must face all the changes experienced by AYA in general, combined with issues related to their chronic condition and its management.\n\nA successful transition involves a transfer of responsibility from parents to AYA regarding the management of their health condition, as well as the acquisition by AYA of knowledge, skills and autonomy. A difficult transition may lead to decreased adherence to follow-up or treatment, deterioration of overall health status and\u002For quality of life, or difficulties in entering adult life.\n\nIn this context, the national cross-sectional study TRANSHEMO was initiated in 2017. Its objective was to compare adherence to healthcare management between two groups of AYA with severe haemophilia (adolescents \\[for whom the transition is ongoing\\] versus young adults \\[for whom the transition may have been completed\\]), and to identify the determinants of this adherence. The results showed that young adults had a lower adherence rate than adolescents (82.2% vs. 61.2%, p\\\u003C0.001). Among the determinants studied, being a young adult, having repeated at least one school year, and presenting psychological and emotional difficulties were factors that had a negative effect on adherence to healthcare management. However, the cross-sectional nature of the study represents a limitation that restricts causal inference. Complementing this project with a longitudinal study would address this limitation.\n\nThe results obtained from this new study (TRANSHEMO 2) may contribute to the literature by providing insights into both the determinants of sustained adherence to healthcare management among adolescents with severe haemophilia who become young adults, and the associations between these determinants.\n\nThe longitudinal design of the project will allow the establishment of a higher level of causal inference between the maintenance of adherence during the transition to adult life and its determinants, which represents a major epidemiological strength. Moreover, results addressing the issue of transition in the context of chronic diseases and derived from longitudinal studies remain scarce, making the findings of this project particularly original. Finally, haemophilia, a relatively frequent condition among rare diseases, could represent an interesting model for understanding the impact of transition in this type of pathology.\n\nStudy hypothesis The extent of the reduction in adherence to healthcare during the transition process, and\u002For the determinants of the maintenance of adherence identified in the longitudinal TRANSHEMO 2 project, may differ from those highlighted in the original cross-sectional TRANSHEMO project.\n\nSpecific aims\n\nMain objective:\n\nTo compare the rate of adherence to healthcare among adolescents who participated in the TRANSHEMO project, using data collected during the original TRANSHEMO study when they were adolescents (before transition) and data to be collected as part of the TRANSHEMO 2 study when they have become young adults (after transition).\n\nSecondary objective:\n\nTo identify the determinants of the maintenance of this adherence and the associations between these determinants, within the framework of a longitudinal study.",[25],[84,85,86,87,88],"haemophilia","young adult","cohort study","genetic disorder","healthcare management","NOT_YET_RECRUITING","2026-02-11",{"date":92,"type":37},"2026-02-18",{"date":94,"type":21},"2026-02",{"date":96,"type":21},"2027-06",{"name":98,"class":44},"Assistance Publique Hopitaux De Marseille",25]